• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Sphenoid plasmacytoma as initial presentation of multiple myeloma-case report

by | Apr 4, 2024 | Publications

J Surg Case Rep. 2024 Apr 1;2024(4):rjae199. doi: 10.1093/jscr/rjae199. eCollection 2024 Apr. ABSTRACT Plasmacytoma is a rare plasma cell neoplasm. Whether solitary or associated with multiple myeloma (MM), it rarely involves the skull base, particularly the sphenoid...

Perifoveal exudative vascular anomalous complex (PEVAC) resembling lesion in a patient with multiple myeloma

by | Apr 4, 2024 | Publications

Am J Ophthalmol Case Rep. 2023 Jul 16;34:101891. doi: 10.1016/j.ajoc.2023.101891. eCollection 2024 Jun. ABSTRACT PURPOSE: To report a case of a perifoveal exudative vascular anomalous complex (PEVAC) resembling lesion in a patient with multiple myeloma. OBSERVATIONS:...

Non-POEMS osteosclerotic multiple myeloma: Clinical characteristics and differential diagnosis

by | Apr 4, 2024 | Publications

J Bone Oncol. 2024 Mar 19;45:100595. doi: 10.1016/j.jbo.2024.100595. eCollection 2024 Apr. ABSTRACT Osteosclerosis in multiple myeloma (MM) is typically associated with rare POEMS syndrome, characterized by polyneuropathy (P), organomegaly (O), endocrinopathy (E),...

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma

by | Apr 4, 2024 | Publications

Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285205. Online ahead of print. ABSTRACT Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a...

Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant

by | Apr 3, 2024 | Publications

Hemasphere. 2024 Apr 1;8(4):e63. doi: 10.1002/hem3.63. eCollection 2024 Apr. ABSTRACT Circulating tumor plasma cells (CTPCs) provide a noninvasive alternative for measuring tumor burden in newly diagnosed multiple myeloma (NDMM). Moreover, measurable residual disease...

Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma

by | Apr 3, 2024 | Publications

BMC Cancer. 2024 Apr 2;24(1):406. doi: 10.1186/s12885-024-12077-0. ABSTRACT BACKGROUND: Autologous stem-cell transplantation (ASCT) remains a beneficial approach for patients with newly diagnosed multiple myeloma (NDMM) in the age of novel therapeutic agents....
« Older Entries
Next Entries »

Recent Content

  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Blood Test Could Replace Bone Marrow Biopsies in Multiple Myeloma
  • Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis
  • Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impact
  • SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT